Literature DB >> 14970095

Randomized clinical trials: what gets published, and when?

Laurence Hirsch1.   

Abstract

Keywords:  Biomedical and Behavioral Research

Mesh：

Year:  2004        PMID： 14970095      PMCID： PMC332714     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  27 in total

1.  Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis.

Authors:  H K Johansen; P C Gotzsche
Journal:  JAMA       Date:  1999-11-10       Impact factor: 56.272

Review 2.  Publication bias: a brief review for clinicians.

Authors:  V M Montori; M Smieja; G H Guyatt
Journal:  Mayo Clin Proc       Date:  2000-12       Impact factor: 7.616

3.  Randomized clinical trials in HEPATOLOGY: predictors of quality.

Authors:  L L Kjaergard; D Nikolova; C Gluud
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

4.  Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology.

Authors:  K S Knox; J R Adams; B Djulbegovic; T J Stinson; C Tomor; C L Bennet
Journal:  Ann Oncol       Date:  2000-12       Impact factor: 32.976

5.  The uncertainty principle and industry-sponsored research.

Authors:  B Djulbegovic; M Lacevic; A Cantor; K K Fields; C L Bennett; J R Adams; N M Kuderer; G H Lyman
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

6.  Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ.

Authors:  Lise L Kjaergard; Bodil Als-Nielsen
Journal:  BMJ       Date:  2002-08-03

7.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

Authors:  B Pitt; P A Poole-Wilson; R Segal; F A Martinez; K Dickstein; A J Camm; M A Konstam; G Riegger; G H Klinger; J Neaton; D Sharma; B Thiyagarajan
Journal:  Lancet       Date:  2000-05-06       Impact factor: 79.321

8.  Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.

Authors:  E J Topol; D J Moliterno; H C Herrmann; E R Powers; C L Grines; D J Cohen; E A Cohen; M Bertrand; F J Neumann; G W Stone; P M DiBattiste; L Demopoulos
Journal:  N Engl J Med       Date:  2001-06-21       Impact factor: 91.245

9.  Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials.

Authors:  J P Ioannidis
Journal:  JAMA       Date:  1998-01-28       Impact factor: 56.272

Review 10.  Conflicts of interest in drug development: the practices of Merck & Co., Inc.

Authors:  Laurence J Hirsch
Journal:  Sci Eng Ethics       Date:  2002-07       Impact factor: 3.525
View more
  4 in total

1.  SSRI treatment for under-18s.

Authors:  Mark A Voysey
Journal:  CMAJ       Date:  2004-06-08       Impact factor: 8.262

2.  Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals.

Authors:  F Alfonso; A Timmis; F J Pinto; G Ambrosio; H Ector; P Kulakowski; P Vardas
Journal:  Neth Heart J       Date:  2012-06       Impact factor: 2.380

3.  Conflicts of interest, authorship, and disclosures in industry-related scientific publications: the tort bar and editorial oversight of medical journals.

Authors:  Laurence J Hirsch
Journal:  Mayo Clin Proc       Date:  2009-09       Impact factor: 7.616

Review 4.  Industry and evidence-based medicine: Believable or conflicted? A systematic review of the surgical literature.

Authors:  Chris S Bailey; Michael G Fehlings; Y Raja Rampersaud; Hamilton Hall; Eugene K Wai; Charles G Fisher
Journal:  Can J Surg       Date:  2011-10       Impact factor: 2.089
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.